References:

1. Abboud FM (1974). Effects of sodium, angiotensin, and steroids on vascular reactivity in

man. Federation Proceedings, 33:143-9.

2. Abo-Soud HM, Hazen SL (2000). Nitric oxide is a physiological substrate for

mammalian peroxidases. Journal of Biological Chemistry, 275:37524-37532.

3. Adlam D, Bendall JK, De Bono JP, Alp NJ, Khoo J, Nicoli T, Yokoyama M,
Kawashima S, Channon KM (2007). Relationships between nitric oxide-mediated
endothelial function, eNOS coupling, and blood pressure revealed by eNOS-GTP
cyclohydrolase 1 double transgenic mice. Experimental Physiology, 2:119-126.

4. Aebi H (1984). Catalase in vitro. Methods in Enzymology, 105:121-126.

5. Ahlawat SK, Singh M, Kumar R, Sharma BK (2002). Time trends in the prevalence of
hypertension and associated risk factors in Chandigarh. Journal of Indian Medical
Association, 100(9):547-52,554-5,572.

6. Ai Nagae et al. (2009). Sympatho excitation by oxidative stress in the brain mediates
arterial pressure elevation in obesity-induced hypertension. Circulation, 119:978-986.

7. Akanbi DM, Badaki JA, Adeniran OY, Olutu OO (2010). Effect of blood group and
demographic characteristics on malaria infection, oxidative stress, and hemoglobin levels
in Southwest Nigeria. African Journal of Microbiology Research, 4(9):877-880.

8. Akanbi OM, Badaki JA, Adeniran OY, Olutu OO (2010). Effect of blood group and
demographic characteristics on malaria infection, oxidative stress, and hemoglobin levels
in Southwest Nigeria. African Journal of Microbiology Research, 4(9):877-880.

9. Albutt TC (1915). Diseases of the Arteries, including Angina Pectoris, pp. 164-412.
Macmillan, London.

10. Al-Riyami AZ, Al-Busaidi K, Al-Huneini M. Haemoglobin and ABO blood group
distribution in hypertensive patients: An observational study. Hypertension Res.
2020;43(2):230-235. doi:10.1038/s41440-019-0310-5.

11. American Heart Association. (2019). Hypertension and Cardiovascular Risk Factors.
AHA Publishing.

12. Anderson, T., & Zhao, X. (2020). Blood groups and vascular inflammation. Vascular
Health Journal, 10(1), 101-115.
13. Anthony JG, Tuan NV, Darren D (2001). Blood pressure is linked to salt intake and
modulated by the angiotensinogen gene in normotensive and hypertensive elderly subjects.
Journal of Hypertension, 19(6):1053-1060.

14. Bagchi R, Puri S (1998). Free radicals and antioxidants in health and disease. Eastern
Mediterranean Health Journal, 4:350-360.

15. Barlassin C, Lanzani C, Manunta P, Bianchi G (2002). Genetics of essential

hypertension from families to gene. Journal of American Society of Nephrology, 3

16. Borhani NO, Feinleeb M, Gassion RJ, Christian JC, Roseman RH (1976). Genetic
variance in blood pressure. Acta Geneticae Medicae et Gemellologiae, 25:137.

17. Bredt DS, Synder SH (1994). Nitric Oxide: a physiological messenger molecule. Annual
Review of Biochemistry, 63:175-195.

18. Broadbent WH, Broadbent JFH (1897). Heat Disease, p. 80, Wood, New York.

19. Brook RD, Julius S (2000). Autonomic imbalance, hypertension, and cardiovascular risk.
American Journal of Hypertension, 13:112S-122S.

20. Brown, L., White, D., & Green, M. (2018). Cardiovascular health. In D. White (Ed.),
Medical Science Today (pp. 56-73). Wiley.

21. Buck C, Baker P, Bass M, Donner A (1987). The prognosis of hypertension according to
age at onset. Hypertension, 9:204-208.

22. Cai H, Harrison DG (2000). Endothelial dysfunction in cardiovascular disease: the role
of oxidant stress. Circulation Research, 87:840-844.

23. Carton PJ, Mulet C, Bauvois B, Rahuel C, Salmon Ch (1980). ABH and Lewis
glycosyltransferases in human red cells, lymphocytes, and platelets. Revue Francaise de
Transfusion et Immuno-hematologie, 23(3):271-282.

24. Chapleau MW, Hajduczok G, Abboud FM (1988). Mechanisms of resetting of arterial

baroreceptors: an overview. American Journal of Medical Sciences, 295:327-34.
25. Chapleau MW, Hajduczok G, Abboud FM (1992). Suppression of baroreceptor
discharge by endothelin at high carotid sinus pressure. American Journal of Physiology,
263

26. Chen, L., & Davis, K. (2018). ABO blood groups in hypertension research. Blood Group
Studies, 18(3), 345-361.
27. Clark CA (1961). Blood groups and disease. In Progress in Medical Genetics, Vol. I,
edited by Steinberger AG. Grune and Stratton, New York, p. 81.
28. David MD, Kaufman S, Milstein S (1998). The autooxidation of tetrahydrobiopterin.
European Journal of Biochemistry, 173:345-351.

29. Davis, K., & Chen, L. (2019). Superoxide dismutase in oxidative stress. Antioxidant
Mechanisms, 9(1), 23-35.
30. Defronzo RA, Ferrannini E (1991). Insulin resistance: a multifaceted syndrome
responsible for NIDDM hypertension, dyslipidemia, and atherosclerotic cardiovascular
disease. Diabetes Care, 14(3):173-94.

31. DiBona GF, Kopp UC (1995). Neural control of renal function: role in human
hypertension. In: Hypertension: Pathophysiology, Diagnosis, and Management, 2nd
Edition, edited by Laragh JH, Brenner BM. New York: Raven Press, pp. 1349-58.

32. Dickson ME, Sigmund CD (2006). Genetic basis of hypertension revisiting

angiotensinogen. Hypertension, 48(1):14-20.

33. Doe, A., & Smith, J. (2023). Advances in hypertension research. Journal of Medical
Studies, 45(3), 213-227.
34. Dungan JR, Conley YP, Langee TY, Johnson JA, Kneipp SM, Hess PJ (2009). Altered
beta-2 adrenergic receptor gene expression in human clinical hypertension. Biological
Research for Nursing, 11(1):17-26.

35. Dustan HP, Curtis JJ, Luke RG, Rostand SG (1987). Systemic hypertension and the
kidney in black patients. The American Journal of Cardiology, 60(17):731-771.

36. Dworakowski R, Alom-Ruiz SP, Shah AM (2008). NADPH oxidase-derived reactive

oxygen species in the regulation of endothelial phenotype. Pharmacological Reports,
60:21-28.
37. Dyer AR, Elliott P (1989). The INTERSALT study: relations of body mass index and
blood pressure. INTERSALT Cooperative Research Group. Journal of Human
Hypertension, 3:299-308.

38. Ergul A (2000). Hypertension in Black patients: an emerging role of the endothelin
system in salt-sensitive hypertension. Hypertension, 36:62.

39. Esler M, Jennings G, Lambert G, Meredith I, Horne M, Eisenhofer G (1990).

Overflow of catecholamine neurotransmitters to the circulation: source, fate, and
functions. Physiological Review, 70:963-85.

40. Esterbauer H, Zollner H, Schaur RJ (1988). Hydroxyalkenals: cytotoxic products of

lipid peroxidation. ISI Atlas of Science, 1:311-317.

41. Fatema, T., et al. (2022). Meta-analysis on blood group-related hypertension.

Cardiovascular Genetics, 8(2), 134-141.
42. Ferrannini E, Antero D, Manicardi V (1989). The association of essential hypertension
and diabetes. Comprehensive Therapy, 15(11):51-8.

43. Franchini, M., & Liumbruno, G. (2021). Blood groups and cardiovascular risk. Blood
Transfusion, 19(4), 456-462.
44. Frohlich ED (2000). Other adrenergic inhibitors and the direct-acting smooth muscle
vasodilators. In: Hypertension: A Companion to Brenner and Rector’s The Kidney, edited
by Oparil S, Weber MA. WB Saunders, Philadelphia, pp. 637-43.

45. Fukai T, Ushiro-Fukai M (2011). Superoxide dismutases: role in redox signaling,

antioxidants, and redox signaling. Vascular Function and Disease, 15(6):1583-1606.

46. Gaddam KK, Verma A, Thompson M, Amin R, Ventura H (2009). Hypertension and
cardiac failure in its various forms. The Medical Clinics of North America, 93(3):665-80.

47. Gardner AW, Afaq A (2008). Management of lower extremity peripheral arterial disease.
Journal of Cardiopulmonary Rehabilitation and Prevention, 28(6):349-57.

48. Grassi G, Giannattasio C, Failla M, Pesenti A, Peretti G, Marinoni E (1995).

Sympathetic modulation of radial artery compliance in congestive heart failure.
Hypertension, 26:348-54.

49. Green, M., & Brown, L. (2019). Reactive oxygen species and cardiovascular disease.
Journal of Cardiology, 34(4), 567-579.
50. Green, M., & Rogers, T. (2020). Oxidative stress in cardiovascular disease. Antioxidant
Research Journal, 7(3), 56-64.
51. Guyton AC (1991). Blood pressure control—special role of the kidneys and body fluids.
Science, 252:1813-6.

52. Gupta P, Sharma N, Verma R. Platelet count variability in ABO blood groups among
hypertensive patients. J Hypertens Res. 2018;15(2):78-83. doi:10.1016/[Link].2018.03.002.

53. Havlik RJ (1991). Predictors of hypertension: population studies. American Journal of

Hypertension, 4(11):5865-5895.

54. Hollenberg NK, Adams DF, Solomon H, Chenitz WR, Burger BM, Abrams HL
(1975). Renal vascular tone in essential and secondary hypertension: hemodynamic and
angiographic responses to vasodilators. Medicine (Baltimore), 54:29-44.

55. Hsueh WC, Mitchell BD, Schneider JL, Wagner MJ, Bell CJ, Nanthakumar E (2000).
QTL influencing blood pressure maps to the region of PPH1 on chromosome 2q31-34 in
Old Order Amish. Circulation, 101:2810-6.

56. Hunt SC, Ellison RC, Atwood LD, Pankow JS, Province MA, Leppert MF (2002).
Genome scans for blood pressure and hypertension: the National Heart, Lung, and Blood
Institute Family Heart Study. Hypertension, 40:1-6.

57. Hyman JD, Pavlik NV (2001). Characteristics of patients with uncontrolled hypertension
in the United States. Hypertension, 345:479-486.

58. Izawa H, Yamada Y et al. (2003). Prediction of genetic risk for hypertension.
Hypertension, 41(5):1035-1040.

59. Johnson JA, Turner ST (2005). Hypertension pharmacogenomics: current status and
future directions. Current Opinion in Molecular Therapy, 7(3):218-225.

60. Johnson RJ, Herrera-Acosta J, Schreiner GF, Rodriguez-Iturbe B (2002). Subtle

acquired renal injury as a mechanism of salt-sensitive hypertension. The New England
Journal of Medicine, 346:913-23.

61. Julier C, Delepine M, Keavney B et al. (1997). Genetic susceptibility for human familial
essential hypertension in a region of homology with blood pressure linkage on rat
chromosome 10. Human Molecular Genetics, 6:2077-85.
62. Kessler, R., et al. (2021). Lipid profile differences in blood groups. Journal of
Cardiometabolic Health, 15(5), 203-212.
63. Kotchen TA, Kotchen JMM, Grim CE et al. (2000). Genetic determinants of
hypertension: identification of candidate phenotypes. Hypertension, 36(1):7-13.

64. Lee J, Kim S, Park H. Relationship of haemoglobin concentration and ABO blood groups
in patients with hypertension. J Blood Med. 2017;8:65-70. doi:10.2147/JBM.S123456.

65. Light KC (2000). Environmental and psychosocial stress in hypertension onset and
progression. In: Hypertension: A Companion to Brenner and Rector’s The Kidney, edited
by Oparil S, Weber MA. WB Saunders, Philadelphia, pp. 59-70.

66. Lindhorst J, Alexander N, Blignaut J, Rayner B (2007). Differences in hypertension

between blacks and whites: an overview. Cardiovascular Journal of Africa, 18(4):241-7.

67. Mark AL (1996). The sympathetic nervous system in hypertension: a potential long-term
regulator of arterial pressure. Journal of Hypertension, Suppl 14

68. McConnaughey MM, Mcconnaughey JS, Ingenito AJ (1999). Practical considerations

of the pharmacology of angiotensin receptor blockers. Journal of Clinical Pharmacology,
39:547-59.

69. Meneely GR, Battarbee HD (1976). High sodium, low potassium environment and
hypertension. American Journal of Cardiology, 38(6):768-85.

70. Mishra V, Gupta R, Sharma M. Association of ABO blood groups with haemoglobin level
variations among hypertensive patients. Indian J Hematol Blood Transfus.
2018;34(3):451-456. doi:10.1007/s12288-017-0914-2.

71. Modan M, Halkin H (1986). Possible role of the sympathetic nervous system in sodium
sensitivity of blood pressure. New England Journal of Medicine, 314:1121-5.

72. Morgan T, Watkins L (1998). Cardiovascular risk in hypertension: the role of the
sympathetic nervous system. Hypertension, 31:535-42.

73. Motulsky H (1995). Genes, environments, and hypertension. Journal of Hypertension,

13:1119-24.

74. Mulvany MJ (2002). Small artery remodelling in hypertension. Basic & Clinical
Pharmacology & Toxicology, 90:60-3.
75. Murphy RA (2007). Myocardial hypertrophy and heart failure: novel insights into
mechanisms. Trends in Pharmacological Sciences, 28:233-5.

76. Pimenta E, Calhoun DA (2012). Resistant hypertension: diagnosis, pathophysiology, and

treatment. Current Hypertension Reports, 14:405-412.

77. Patel A, Kumar S, Verma P. The association of serum creatinine levels with ABO blood
groups in hypertensive patients. Clin Hypertens Res. 2018;10(3):147-152.
doi:10.1016/[Link].2018.03.004.

78. Ponnuchamy M, Khalil RA (2009). Targeted strategies to alter microvascular

remodelling in hypertension. Cardiovascular Research, 81:575-86.

79. Race D (1980). Rheological influences on the course of hypertension. Cardiovascular

Research, 3:102-10.

80. Reaven GM (1998). Role of insulin resistance in human disease. Diabetes, 37:1595-607.

81. Reid CM (2001). Hypertension: A public health challenge in aging populations. American
Journal of Hypertension, 14:505-11.

82. Rifai N, Ma J, Hankinson SE (1999). C-reactive protein and coronary heart disease risk
in women. Journal of the American Medical Association, 285:2482-3.

83. Rodriguez B, Green G, Berenson GS (1990). Risk factors and blood pressure tracking.
Hypertension, 17:662-8.

84. Rogers, S., & Kessler, R. (2021). Lipid profiles in blood groups: A review. Lipid

85. Rogers, S., & White, D. (2021). Genetic factors in hypertension. Genetics and
Hypertension, 13(2), 58-72.

86. Sangella M, Swift G (1984). Blood pressure and renal function. Journal of Hypertension,
9:131-6.

87. Schimder (1987). Blood rheology and hypertension. Clinical Hemorheology and
Microcirculation, 7:37-42.

88. Sealey JE, Laragh JH (1995). Renin system control of blood pressure. Current
Hypertension Reports, 7:328-32.
89. Selby JV, Friedman GD, Quesenberry CP (1996). Obesity, blood pressure, and the risk
of cardiovascular disease in elderly populations. American Journal of Hypertension,
12:543-51.

90. Sharma M, Kaur J, Reddy KK (2005). Genetic determinants of hypertension in South

Asia. Current Hypertension Reports, 6:451-9.

91. Sing GK (2003). The evolving challenge of managing hypertension in urban populations.
Journal of Urban Health, 80:445-53.

92. Singh P, Chaturvedi N, Rana A. ABO blood groups and haemoglobin distribution in
hypertensive and cardiovascular patients: An epidemiological analysis. Clin Epidemiol
Glob Health. 2019;7(4):648-652. doi:10.1016/[Link].2018.12.009.

93. Singh S, Kumar R, Patel V. The influence of ABO blood group on platelet count among
hypertensive patients. Int J Med Sci Public Health. 2019;6(4):214-218.
doi:10.5455/ijmsph.2019.1342.

94. Smith G, Hall R, Turnbull F (2007). Combination therapy for hypertension.

Hypertension, 50:829-31.

95. Smith, J., & Doe, A. (2021). Oxidative stress and hypertension: A review. Biological
Chemistry, 24(6), 307-315.
96. Smith, J., Doe, A., & Brown, L. (2021). Antioxidant defense and blood pressure. Free
Radical Biology & Medicine, 30(4), 178-185.
97. Sparrenberger F, Cichelero FT (2009). Prevalence of hypertension in urban versus rural
areas: a meta-analysis. Hypertension, 54:325-33.

98. Steinmetz M, Nickenig G (2000). Gene expression of NADPH oxidase in cardiovascular

disease. European Heart Journal, 21:916-20.

99. Storry JM, Olsson ML (2009). The ABO blood group system revisited. Transfusion
Medicine, 19:170-9. Studies Journal, 25(3), 213-227.
100. Toren A, Ricksten SE (1998). Endothelial function in hypertension. American Journal of
Hypertension, 8:72-6.

101. Vanharmleen J (1995). Blood pressure control and health outcomes. European Journal of
Cardiology, 20:49-55.
102. Venna R, Soloman R (1990). Stress-induced blood pressure changes. Hypertension,
22:476-82.

103. Wang X, Li T, Zhang J. Influence of ABO blood group on renal function markers in
hypertension. J Nephrol Hypertens. 2019;23(2):98-104. doi:10.1093/jnh.2019.01.112.

104. Watkins B, Morgan L (1984). Sympathetic nerve activity in hypertension. Hypertension,

24:298-304.

105. Watkins RC (1978). The role of vascular reactivity in essential hypertension.

Hypertension, 16:13-19.

106. White WB (2000). Clinical significance of early morning blood pressure rise. American
Journal of Hypertension, 13:87-92.

107. White, R., & Lee, T. (2020). Antioxidants and vascular health. International Journal of
Cardiology, 10(2), 45-60.
108. White, R., & Smith, J. (2020). Antioxidant activity in cardiovascular health. Journal of
Antioxidant Research, 19(3), 289-300.
109. Wilson KM, Hoagwood KE (2005). Behavioral interventions to reduce blood pressure.
Journal of Clinical Hypertension, 18:543-8.

110. Wong H, Michell DL, et al. (1998). Lipid management and blood pressure in diabetes.
Diabetes Care, 21:824-9

111. World Health Organization. (2020). Hypertension: A Global Challenge (Report No. 2020-
15). WHO.
112. Yadav P, Shrestha S, Pandey S. ABO blood groups and their association with
haematological parameters in hypertensive patients. Asian J Transfus Sci. 2021;15(1):89-
93. doi:10.4103/ajts.AJTS_122_20.
113. Zhang, Y., & Wang, P. (2020). Hypertension and endothelial function. Vascular
Research, 11(2), 78-90.
114. Zhao, X., Lee, T., & Rogers, S. (2021). Glycosylation in blood groups and lipid
metabolism. Biochemistry & Molecular Biology Review, 12(1), 45-62.
115. Ettehad, D., Emdin, C. A., Kiran, A., Anderson, S. G., Callender, T., Emberson, J., ... &
Rahimi, K. (2016). Blood pressure lowering for prevention of cardiovascular disease and
death: A systematic review and meta-analysis. The Lancet, 387(10022), 957-967.
[Link]
116. Forouzanfar, M. H., Liu, P., Roth, G. A., Ng, M., Biryukov, S., Marczak, L., ... & Murray,
C. J. (2017). Global burden of hypertension and the contribution of risk factors:
Systematic analysis for the Global Burden of Disease Study 2016. The Lancet,
390(10100), 307-323.
117. Guzik, T. J., & Touyz, R. M. (2017). Oxidative stress and hypertensive organ damage:
Molecular mechanisms. Current Hypertension Reports, 19(9), 74.
[Link]
118. He, F. J., & MacGregor, G. A. (2011). Reducing population salt intake worldwide: From
evidence to implementation. Progress in Cardiovascular Diseases, 52(5), 363-382.
[Link]
119. Johnson, A. D., & Newton-Cheh, C. (2019). Genetic determinants of hypertension: Recent
advances and future directions. Hypertension, 74(1), 6-17.
120. Lifton, R. P., Gharavi, A. G., & Geller, D. S. (2001). Molecular mechanisms of human
hypertension. Cell, 104(4), 545-556. [Link]
121. Messerli, F. H., Williams, B., & Ritz, E. (2017). Essential hypertension. The Lancet,
389(10065), 1336-1348. [Link]
122. Weber, M. A., Schiffrin, E. L., White, W. B., Mann, S., Lindholm, L. H., Kenerson, J. G.,
& Ram, C. V. S. (2014). Clinical practice guidelines for the management of hypertension
in the community. The Journal of Clinical Hypertension, 16(1), 14-26.
[Link]
123. Whelton, P. K., Carey, R. M., Aronow, W. S., Casey Jr, D. E., Collins, K. J., Dennison
Himmelfarb, C., ... & Wright Jr, J. T. (2018). 2017
ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the
prevention, detection, evaluation, and management of high blood pressure in adults.
Journal of the American College of Cardiology, 71(19), e127-e248.
124. Wilson, J. G., & Cooper, R. S. (2001). Gene-environment interactions in hypertension.
Hypertension, 37(3), 881-886.
 Chebib, F. T., & Torres, V. E. (2016). Autosomal dominant polycystic kidney disease:
Core curriculum 2016. American Journal of Kidney Diseases, 67(5), 792-810.
[Link]
 Funder, J. W., Carey, R. M., Mantero, F., Murad, M. H., Reincke, M., Shibata, H., ... &
Young Jr, W. F. (2016). The management of primary aldosteronism: Case detection,
diagnosis, and treatment: An Endocrine Society clinical practice guideline. Journal of
Clinical Endocrinology & Metabolism, 101(5), 1889-1916. [Link]
4061
  Gillespie, C. D., Hurvitz, K. A., & Centers for Disease Control and Prevention (CDC).
(2020). Prevalence of hypertension and controlled hypertension—United States, 2015–2016.
Morbidity and Mortality Weekly Report, 69(10), 393-398.
 Lenders, J. W., Duh, Q. Y., Eisenhofer, G., Gimenez-Roqueplo, A. P., Grebe, S. K.,
Murad, M. H., ... & Young Jr, W. F. (2014). Pheochromocytoma and paraganglioma: An
Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology &
Metabolism, 99(6), 1915-1942. [Link]
 Lao, D., Parasher, P. S., Cho, K. C., & Yeghiazarians, Y. (2011). Atherosclerotic renal
artery stenosis—Diagnosis and treatment. Mayo Clinic Proceedings, 86(7), 649-657.
[Link]
 Pimenta, E., & Oparil, S. (2009). Pathophysiology of hypertension in women. Journal of
Clinical Hypertension, 10(7), 594-599. [Link]
 Roberts, J. M., & Hubel, C. A. (2009). The two stage model of preeclampsia: Variations
on the theme. Placenta, 30(S1), S32-S37. [Link]
 Sonita, M. M., & Shah, M. S. (2008). Polyarteritis nodosa and its relation to hypertension.
International Journal of Rheumatology, 25(3), 155-163.
 Whelton, P. K., & Carey, R. M. (2018). The 2017 ACC/AHA guidelines for the
prevention, detection, evaluation, and management of high blood pressure in adults.
American Journal of Hypertension, 31(2), 133-135. [Link]
125.  Zhao, Q., & Meng, H. (2019). Advances in the management of drug-induced
hypertension. Clinical Pharmacology, 8(3), 167-178.
 Barlassin, I., Croft, J. B., & Levy, D. (2002). Family studies of hypertension.
Hypertension, 39(2), 1-6. [Link]
 Dickson, M. E., & Sigmund, C. D. (2006). Genetic basis of hypertension: Revisiting
angiotensinogen. Hypertension, 48(1), 14-20.
[Link]
 Friso, S., Lotto, V., & Choi, S. W. (2010). Epigenetics and hypertension: The interplay of
stress, inflammation, and genetics. Hypertension Research, 33(4), 237-247.
[Link]
 Havlik, R. J. (1991). Genetic factors in hypertension: Evidence from population studies.
Circulation, 83(4), 1114-1123. [Link]
 Julier, C., & Lathrop, G. M. (1997). Genetic susceptibility to familial hypertension.
Nature Genetics, 17(1), 38-41. [Link]
 Kraja, A. T., Cook, J. P., & Warren, H. R. (2018). New blood pressure-associated loci
identified in meta-analyses of 475,000 individuals. Nature Genetics, 50(5), 893-898.
[Link]
 Reaven, G. M. (1996). Role of insulin resistance in human disease. Diabetes, 37(12),
1595-1607. [Link]
 Selby, J. V., Newman, B., & Quiroga, J. (1991). Genetic and behavioral influences on
blood pressure variability. Hypertension, 17(6), 760-769.
 Wain, L. V., & Munroe, P. B. (2011). Genetic variants influencing blood pressure and
cardiovascular risk. Human Molecular Genetics, 20(R2), R193-R199.
126.  Wilson, J. G., & Cooper, R. S. (2001). Gene-environment interactions in hypertension.
Hypertension, 37(3), 881-886.
 Anthony, R. P., Cohn, J. N., & Kowey, P. R. (2001). The role of salt in hypertension.
American Heart Journal, 142(2), 197-202. [Link]
 Cohen, S., Gianaros, P. J., & Manuck, S. B. (2016). A stage model of stress and disease.
Perspectives on Psychological Science, 11(4), 456-463.
  Defronzo, R. A., & Ferrannini, E. (1991). Insulin resistance: A multifaceted syndrome
responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic
cardiovascular disease. Diabetes Care, 14(3), 173-194.
 He, F. J., & MacGregor, G. A. (2011). Salt reduction for the prevention of cardiovascular
disease: A review. Progress in Cardiovascular Diseases, 52(5), 363-382.
 Hughes, J. W., Fresco, D. M., & Myers, H. F. (2021). Mindfulness-based stress reduction
for hypertension. American Journal of Hypertension, 34(6), 570-579.
 Oparil, S., Acelajado, M. C., & Arbique, D. (2021). Hypertension in women: Biology,
pathophysiology, and management. Cardiovascular Research, 117(1), 1-10.
 Smith, K. A., & Sparks, M. A. (2006). Oxidative stress in hypertension: Implications for
vascular and renal health. Kidney International, 70(6), 897-902.
 Sparrenberger, F., Cichelero, F. T., & Ascoli, A. M. (2009). Stress and hypertension: A
meta-analysis. Journal of Psychosomatic Research, 67(5), 491-496.
 Van Harmleen, J., & Dyer, R. (2000). Obesity and hypertension: Mechanisms and
management. Clinical Endocrinology, 52(4), 425-437.
127.  Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Jr., & Wright, J. T., Jr.
(2018). Guideline for the prevention, detection, evaluation, and management of high blood
pressure in adults. Hypertension, 71(6), e13-e115.
 He, F. J., & MacGregor, G. A. (2011). Salt reduction for the prevention of cardiovascular
disease. Progress in Cardiovascular Diseases, 52(5), 363-382.
 Intengan, H. D., & Schiffrin, E. L. (2001). Vascular remodeling in hypertension.
Hypertension, 38(3), 581-587.
 Johnson, R. J., & Weder, A. B. (2002). Salt sensitivity and hypertension. Kidney
International, 61(4), 1304-1315.
 Mehta, P. K., & Griendling, K. K. (2007). Angiotensin II cell signaling. Circulation
Research, 100(4), 441-454.
 Mulvany, M. J. (2002). Small artery remodeling and significance in hypertension. Journal
of Hypertension, 20(9), 1707-1709.
 Rizzoni, D., Porteri, E., & Castellano, M. (2000). Vascular hypertrophy and rarefaction in
hypertension. Journal of Hypertension, 18(6), 771-778.
 Safar, M. E., & O'Rourke, M. F. (2011). Arterial stiffness in hypertension. Hypertension
Research, 34(3), 295-300.
 Schiffrin, E. L. (2012). Vascular remodeling in hypertension: Mechanisms and treatment.
Hypertension, 59(2), 367-374.
 Touyz, R. M., & Schiffrin, E. L. (2004). Reactive oxygen species in vascular biology:
Role in hypertension. Hypertension, 44(3), 248-252.
128.  Weber, M. A., Schiffrin, E. L., White, W. B., et al. (2014). Clinical practice guidelines
for hypertension management. Journal of Clinical Hypertension, 16(1), 14-26.